AstraZeneca's immunotherapy drug scores key Phase III lung cancer win - MedCity News

AstraZeneca's immunotherapy drug scores key Phase III lung cancer win  MedCity News

The company said the Phase III CASPIAN study of Imfinzi in first-line, extensive-stage small-cell lung cancer was successful, but did not disclose further details.



Comments

Popular posts from this blog